About Tango Therapeutics, Inc. - Common Stock (TNGX)
Tango Therapeutics Inc is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company specializes in understanding the genetic and biological drivers of cancer, utilizing its expertise in synthetic lethality to create targeted treatments that aim to exploit specific vulnerabilities in cancer cells. Tango Therapeutics employs cutting-edge research and drug discovery techniques to identify and develop novel compounds that can improve patient outcomes, emphasizing precision medicine and personalized treatment approaches in oncology. Through their work, they aim to contribute significantly to the advancement of cancer care and the improvement of therapeutic options available to patients. Read More
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.
